Novo Nordisk has received a second warning letter from the FDA in less than a month, this time over an advertisement promoting its blockbuster diabetes drug Ozempic. In a Feb. 26 letter, the FDA said a direct-to-consumer television advertisement titled…
GLP-1s
The FDA has issued 30 warning letters to telehealth companies for making false or misleading claims about compounded GLP-1 products on their websites. The letters cite violations including claims implying compounded products are the same as FDA-approved drugs, and advertising…
GLP-1 drugs may slightly raise the risk of osteoporosis, according to a pair of new studies. In one study, presented March 2 at the American Academy of Orthopaedic Surgeons’ annual meeting, researchers evaluated five years of medical records from more…
Novo Nordisk has partnered with Vivtex Corp. to develop next-generation oral biologic medicines for obesity, diabetes and related conditions. Under the agreement, Vivtex will license its proprietary oral drug-delivery technologies to Novo Nordisk and is eligible to receive up to…
Walgreens has expanded its virtual care platform to include weight management services, offering $49 clinician-guided visits for eligible adults using GLP-1 therapies. The new Walgreens Weight Management program is open to self-pay patients ages 18-64 who are overweight or have…
Advertisement
Novo Nordisk will reduce the U.S. list price of Wegovy, Ozempic and Rybelsus to $675 per month starting Jan. 1, 2027. The change constitutes a list price reduction of approximately 50% for Wegovy and 35% for Ozempic across all doses,…
A Novo Nordisk-led study comparing CagriSema, its GLP-1 drug candidate for obesity, found that Eli Lilly’s Zepbound resulted in greater weight loss. The open-label, head-to-head trial analyzed the average weight loss among adults who received weekly injections of either CagriSema…
Eli Lilly has launched a multidose version of its blockbuster weight loss drug Zepbound that gives patients a month’s worth of treatment in a single injection pen. On Feb. 23, the drugmaker said the FDA approved a label expansion for…
Eli Lilly has reported positive results from its phase 3b Together-PsO trial evaluating the combined use of Taltz (ixekizumab) and Zepbound (tirzepatide) in adults with plaque psoriasis and obesity or overweight. At 36 weeks, 27.1% of patients receiving both drugs…
In a comparative study evaluating SGLT2 inhibitors and GLP-1 medications, the former drug class was associated with lower risk of chronic kidney disease and acute kidney injury. The study, published Jan. 20 in JAMA, analyzed the comparative effectiveness of both…